Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ArriVent BioPharma (AVBP) Interest & Investment Income (2023 - 2026)

ArriVent BioPharma has reported Interest & Investment Income over the past 4 years, most recently at $2.8 million for Q1 2026.

  • Quarterly results put Interest & Investment Income at $2.8 million for Q1 2026, up 17.02% from a year ago — trailing twelve months through Mar 2026 was $11.6 million (down 10.16% YoY), and the annual figure for FY2025 was $11.2 million, down 18.77%.
  • Interest & Investment Income reached $2.8 million in Q1 2026 per AVBP's latest filing, down from $3.3 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $3.8 million in Q2 2024 and bottomed at $1.0 million in Q2 2023.
  • Median Interest & Investment Income over the past 4 years was $2.9 million (2024), compared with a mean of $2.8 million.
  • The largest annual shift saw Interest & Investment Income skyrocketed 275.91% in 2024 before it tumbled 41.83% in 2025.
  • Over 4 years, Interest & Investment Income stood at $1.9 million in 2023, then surged by 59.58% to $3.1 million in 2024, then increased by 6.74% to $3.3 million in 2025, then dropped by 14.88% to $2.8 million in 2026.
  • Business Quant data shows Interest & Investment Income for AVBP at $2.8 million in Q1 2026, $3.3 million in Q4 2025, and $3.3 million in Q3 2025.